文献速递肝病

8周与12周来迪派韦/索磷布韦方案治疗基因6型初治或经治丙型肝炎患者的开放标签研究

Open Label Study of 8 vs. 12 Weeks of Ledipasvir/Sofosbuvir in Genotype 6 Treatment Naïve or Experienced Patients.
PubMed 文献 · Am J Gastroenterol · 2017-10-31

该前瞻性研究在美国4个中心纳入60例基因6型丙型肝炎患者,无肝硬化初治者接受8周来迪派韦/索磷布韦固定剂量复方制剂(LDV/SOF FDC)治疗,肝硬化或经治者接受12周治疗,8周组与12周组持续病毒学应答12周(SVR12)均为95.0%,不良事件包括乏力、失眠、头痛和恶心,所有患者均完成既定疗程。

要点

  • 无肝硬化初治基因6型丙型肝炎患者接受8周LDV/SOF FDC,SVR12为95.0%(19/20)。
  • 肝硬化或经治基因6型丙型肝炎患者接受12周LDV/SOF FDC,SVR12为95.0%(38/40)。
  • 不良事件包括乏力(5%)、失眠(3.3%)、头痛(1.7%)和恶心(1.7%),所有患者均完成既定疗程。

核心结论

  • 8周或12周LDV/SOF FDC分别对无肝硬化或无既往治疗失败患者以及肝硬化或既往治疗失败患者安全有效。

研究设计与样本

  • 前瞻性开放标签研究,在美国4个中心纳入60例基因6型丙型肝炎患者,无肝硬化初治者接受8周LDV/SOF FDC,肝硬化或经治者接受12周LDV/SOF FDC。

主要发现

  • 总体平均年龄58±10岁,男性占58%,所有患者均为亚洲出生且国外出生。
  • 8周组20例(33.3%),12周组40例(66.7%);12周组中有2例(5%)失代偿、3例(7.5%)肝癌、14例(35%)既往治疗。
  • 8周组SVR12为95.0%(19/20),12周组SVR12为95.0%(38/40)。
  • 不良事件包括乏力(5%)、失眠(3.3%)、头痛(1.7%)和恶心(1.7%),所有患者均完成既定疗程;发生2例与治疗无关的严重不良事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Hepatitis C genotype 6 (HCV-GT6) is one of the most prevalent genotypes in Southeast Asia. Ledipasvir and sofosbuvir fixed-dose combination (LDV/SOF FDC) for 12 weeks has been shown to be effective for multiple HCV genotypes including treatment-naïve HCV-6. Our goal was to examine treatment outcomes in a diverse HCV-6 population. METHODS: We prospectively enrolled 60 HCV-GT6 patients at four US centers. Treatment -naïve without cirrhosis patients received open-labeled LDV/SOF FDC orally once a day for 8 weeks; All cirrhotic and/or treatment-experienced patients received LDV/SOF FDC for 12 weeks. The primary outcome was sustained virological response 12 weeks after therapy (SVR12). Secondary outcomes were adverse events (AEs) and/or serious adverse events (SAEs). All patients gave written consent. RESULTS: Overall mean age was 58±10 and 58% were male. All patients were Asian and foreign born. The 8-week group included 20 patients (33.3%) and the 12-week included 40 patients (66.7%). There were 2 (5%) patients with decompensation, 3 with liver cancer (7.5%), and 14 with prior treatment (35%) in the 12-week group. SVR12 was 95.0% for the 8-week group (19/20) and 95.0% for the 12-week group (38/40). AEs included fatigue (5%), insomnia (3.3%), headache (1.7%), and nausea (1.7%); however, all patients completed the intended treatment duration. There were two treatment-unrelated SAEs. CONCLUSIONS: LDV/SOF FDC for 8 or 12 weeks was safe and effective for patients without cirrhosis or prior treatment failure as well as for patients with cirrhosis and/or prior treatment failure, respectively.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Nguyen MH, Trinh H, Do S, et al. Open Label Study of 8 vs. 12 Weeks of Ledipasvir/Sofosbuvir in Genotype 6 Treatment Naïve or Experienced Patients. Am J Gastroenterol. 2017. PMID: 29087397. doi:10.1038/ajg.2017.399

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。